|
|
|
|
| LEADER |
00000cam a2200000Mu 4500 |
| 001 |
ocn871779539 |
| 003 |
OCoLC |
| 005 |
20240623213015.0 |
| 006 |
m o d |
| 007 |
cr |n|---||||| |
| 008 |
140306s2014 gw o 000 0 eng d |
| 040 |
|
|
|a MHW
|b eng
|e pn
|c MHW
|d EBLCP
|d OCLCQ
|d ZCU
|d MERUC
|d ICG
|d OCLCO
|d OCLCF
|d OCLCQ
|d DKC
|d OCLCO
|d AU@
|d OCLCQ
|d SGP
|d OCLCO
|d OCLCQ
|d OCLCO
|d OCLCL
|d UEJ
|
| 020 |
|
|
|a 9783954896981
|
| 020 |
|
|
|a 3954896982
|
| 035 |
|
|
|a (OCoLC)871779539
|
| 043 |
|
|
|a e-gx---
|
| 050 |
|
4 |
|a QH506
|
| 050 |
|
4 |
|a RS380
|
| 049 |
|
|
|a HCDD
|
| 100 |
1 |
|
|a Miera, Jakob.
|
| 245 |
1 |
0 |
|a CRO - Contract Research Organization.
|
| 260 |
|
|
|a Hamburg :
|b Diplomica Verlag,
|c 2014.
|
| 300 |
|
|
|a 1 online resource (91 pages)
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 588 |
0 |
|
|a Print version record.
|
| 520 |
|
|
|a This book deals in general with mergers and acquisitions in the CRO industry, and more specifically with reasons for M and A, success factors during the M and A process, and why M and A can fail in the Contract Research Organization industry. The pharmaceutical industry faces increasing obstacles in respect to the development and introduction of new medications. That has to do with stricter requirements for admission and sharper controls by authorities. Today, the research and development of a new drug can easily consume more than 800 million and lasting between 10 and 15 years. Due to these f.
|
| 505 |
0 |
|
|a CRO -- Contract Research Organization; Index; List of Figures; List of Tables; List of Abbreviations; Introduction; Methodology; 1. Merger & Acquisitions Fundamentals; 1.1 Definition and History; 1.2 Types and history of Merger & Acquisitions; 1.3 Recent M&A Trends; 2. Contract Research Organization Industry; 2.1 The Drug Development Process; 2.2 Fundamentals of Contract Research Organizations; 2.3 Strategic Analysis of the Drug Development Market; 2.4 Growth Strategies in CRO Industry; 3. Explanatory Approaches and Motives for M 3.1 Strategic Motives; 3.2 Financial Motives
|
| 505 |
8 |
|
|a 3.3 Managerial Motives4. Success Factors for the Merger & Acquisitions process; 4.1 Merger & Acquisitions Process; 4.2 Potential Success Factors during the M&A process; 5. Case Study: Merger & Acquisitions in the CRO industry; 5.1 Data & Methodology; 5.2 Why M&A occur in the CRO Industry; 5.3 Potential Success Factors for the M&A process in the CRO industry; 5.4 Reasons for success failures for the M&A process in the CRO industry; 5.5 Determinants and evaluation for success after the M 6. Conclusion and Recommendations; Appendix; Bibliography
|
| 650 |
|
0 |
|a Pharmaceutical biotechnology
|z Germany.
|
| 650 |
|
0 |
|a Biopharmaceutics
|x Economic aspects.
|
| 650 |
|
7 |
|a Pharmaceutical biotechnology
|2 fast
|
| 651 |
|
7 |
|a Germany
|2 fast
|1 https://id.oclc.org/worldcat/entity/E39PBJtCD3rcKcPDx6FHmjvrbd
|
| 758 |
|
|
|i has work:
|a CRO - Contract Research Organization: How Drug Research is Evolving (Text)
|1 https://id.oclc.org/worldcat/entity/E39PCYmvpf878P3xbXkkJvVFqP
|4 https://id.oclc.org/worldcat/ontology/hasWork
|
| 776 |
0 |
8 |
|i Print version:
|z 9783954891986
|
| 856 |
4 |
0 |
|u https://ebookcentral.proquest.com/lib/holycrosscollege-ebooks/detail.action?docID=1640301
|y Click for online access
|
| 903 |
|
|
|a EBC-AC
|
| 994 |
|
|
|a 92
|b HCD
|